{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011878","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.207830+00:00","generated_at":"2026-05-17T14:04:51.167233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sanara MedTech Q2 revenue up 28% to $25.8M; launches strategic review for Tissue Health Plus subsidiary","bullets":["Net revenue $25.8M, up 28% YoY; net loss narrowed to $2.0M from $3.5M.","Adjusted EBITDA $2.7M vs $0.6M in prior-year quarter.","H1 2025: revenue $49.3M (+27%), net loss $5.5M, adjusted EBITDA $3.3M.","Sanara Surgical segment H1 adjusted EBITDA $7.4M vs $2.5M; THP segment adjusted EBITDA -$4.1M vs -$1.6M.","Company initiates process to evaluate strategic alternatives for Tissue Health Plus subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011878","json":"https://secwatch.observer/filing/0001493152-25-011878.json","markdown":"https://secwatch.observer/filing/0001493152-25-011878.md","text":"https://secwatch.observer/filing/0001493152-25-011878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315225011878/0001493152-25-011878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315225011878/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:04:51.167233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}